Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pulmonary circulation 2018-04, Vol.8 (2), p.1-4
Hauptverfasser: Cartin-Ceba, Rodrigo, Halank, Michael, Ghofrani, Hossein-Ardeschir, Humbert, Marc, Mattson, John, Fritsch, Arno, Krowka, Michael
Format: Artikel
Sprache:eng
Schlagworte:
Life Sciences
portal hypertension
pulmonary arterial hypertension
Pulmonary hypertension
Research Letter
soluble guanylate cyclase stimulator
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
ISSN:2045-8940
2045-8932
2045-8940
DOI:10.1177/2045894018769305